MHRA review confirms benefit/risk profile of Alteplase - the only licensed clot buster for acute ischaemic stroke

  • MHRA Expert Working Group reconfirms benefits of specialist stroke medicine Alteplase outweigh the risks, when used within its license.
  • Their conclusions reflect an extensive and thorough review of more than a decade of clinical experience and evidence.

BRACKNELL, England--()--Today, Boehringer Ingelheim received the positive news that, following an expert working group review, on behalf of the Medicines and Healthcare products Regulatory Agency has reconfirmed that the benefits of our specialist stroke medicine Alteplase, outweigh the risks, when used within its license.

This announcement confirms that patients and doctors should have full confidence in our medicine, which is supported by more than a decade of clinical experience.

Charles De Wet, Medical Director for Boehringer Ingelheim in the UK and Ireland said “Our medicine is the only licensed clot buster for acute ischaemic stroke, the shockwaves of which can leave a lasting and profound impact on how people move, see, speak, feel or understand their world.

“The news from MHRA expert working group confirms that our medicine can play a vital role in improving the lives of patients.”

About Boehringer Ingelheim

The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates globally with 146 affiliates and a total of more than 47,700 employees. The focus of the family-owned company, founded in 1885, is researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine.

Social responsibility is an important element of the corporate culture at Boehringer Ingelheim. This includes worldwide involvement in social projects, such as the initiative “Making more Health” and caring for the employees. Respect, equal opportunities and reconciling career and family form the foundation of the mutual cooperation. In everything it does, the company focuses on environmental protection and sustainability.

In 2014, Boehringer Ingelheim achieved net sales of about 13.3 billion euros. R&D expenditure corresponds to 19.9 per cent of its net sales.

For more information please visit www.boehringer-ingelheim.co.uk.

~Ends~

Contacts

Boehringer Ingelheim Limited
Duncan Cantor
Communications Director
Tel: +44 (0)1344 741155
duncan.cantor@boehringer-ingelheim.com

Contacts

Boehringer Ingelheim Limited
Duncan Cantor
Communications Director
Tel: +44 (0)1344 741155
duncan.cantor@boehringer-ingelheim.com